Want to see IN:AKUMS full AI Analyst Report?
AKUMS Stock Chart & Stats
₹420.10
₹13.30(2.17%)
At close: 4:00 PM EST
₹420.10
₹13.30(2.17%)
Day’s Range― - ―
52-Week Range₹410.10 - ₹707.00
Previous CloseN/A
Volume56.90K
Average Volume (3M)11.50K
Market Cap
₹103.57B
Enterprise Value₹75.34B
Total Cash (Recent Filing)₹16.78B
Total Debt (Recent Filing)₹902.87M
Price to Earnings (P/E)42.1
Beta1.32
Next Earnings
Aug 24, 2026EPS Estimate
6.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.42
Shares Outstanding157,393,980
10 Day Avg. Volume12,021
30 Day Avg. Volume11,497
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)2.15
Price to Sales (P/S)1.64
P/FCF Ratio7.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)23.95
Revenue Forecast (FY)₹49.24B
Bulls Say, Bears Say
Bulls Say
Deleveraging / Strong Balance SheetA materially lower debt-to-equity ratio and a larger equity base provide durable financial flexibility. This strengthens the company's ability to fund CDMO capacity, withstand demand volatility, refinance at favorable terms, and pursue organic or small inorganic investments without stressing liquidity.
Improved Cash GenerationMaterial positive free cash flow and operating cash flow in FY26 indicate the business can self-fund working capital and capex. High FCF coverage of net income boosts reinvestment capacity, reduces refinancing reliance, and supports sustained CDMO operations and client servicing.
CDMO Model & Diversified Manufacturing BaseA contract manufacturing model serving multiple therapeutic areas and export markets embeds long-term client relationships and repeat orders. This diversification across products and geographies supports steadier demand, scale benefits, and resilience versus single-product firms.
Bears Say
Margin Compression / Profitability VolatilityA sharp margin step-down signals structural pressure from cost inflation, adverse product mix, pricing pressure, or one-offs. Persistently lower margins would erode cash flow margins, reduce reinvestment ability, and require operational remediation to sustain returns in a competitive generics/CDMO market.
Free Cash Flow VolatilityAlthough FY26 FCF was strong, the decline vs FY25 and historically uneven cash conversion reduce predictability of internal funding. This makes budgeting for capex, working capital, and client-driven scale-ups riskier and increases reliance on disciplined cash management.
Earnings Volatility / Prior LossesSignificant EPS volatility and recent prior losses indicate inconsistent operational performance. This complicates medium-term forecasting, may reflect exposure to one-off items or contract timing, and raises execution risk in sustaining margins and cash conversion across cycles.
Akums Drugs and Pharmaceuticals Limited News
AKUMS FAQ
What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?
Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹410.10 and its highest was ₹707.00 in the past 12 months.
What is Akums Drugs and Pharmaceuticals Limited’s market cap?
Akums Drugs and Pharmaceuticals Limited’s market cap is ₹103.57B.
When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?
Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Aug 24, 2026 which is in 43 days.
How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?
Akums Drugs and Pharmaceuticals Limited released its earnings results on May 14, 2026. The company reported ₹5.5 earnings per share for the quarter, beating the consensus estimate of N/A by ₹5.5.
Is Akums Drugs and Pharmaceuticals Limited overvalued?
According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Overvalued.
Does Akums Drugs and Pharmaceuticals Limited pay dividends?
Akums Drugs and Pharmaceuticals Limited pays a N/A dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Akums Drugs and Pharmaceuticals Limited dividends here
What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?
Akums Drugs and Pharmaceuticals Limited’s EPS estimate is 6.1.
How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?
Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.
What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?
Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹5.5 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.69%.
Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:AKUMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akums Drugs and Pharmaceuticals Limited
Akums Drugs & Pharmaceuticals Ltd. is an Indian-based company, established in 2004 and headquartered in Delhi, that operates globally as a manufacturer and supplier of both finished pharmaceutical products and active pharmaceutical ingredients (APIs). Its diverse product range encompasses conventional drugs, traditional Ayurvedic and herbal remedies, personal care items including toiletries, nutraceuticals, food and dietary supplements, dermatological and cosmetic products, and healthcare and hospital supplies, along with over-the-counter (OTC) solutions. The company also deals in excipients and various chemical compounds. Akums develops and markets its own branded formulations across a variety of dosage forms, such as tablets, capsules, injectables, ophthalmic preparations, and soft gelatin capsules. These products address a broad spectrum of therapeutic areas, including gynaecology, cardiology, orthopaedics, pediatrics, dermatology, anti-infectives, pain management, and gastroenterology. Furthermore, Akums Drugs & Pharmaceuticals provides services as a pharmaceutical contract development and manufacturing organization (CDMO).
Technical Analysis
Glenmark Life Sciences Limited
―
Jubilant Pharmova Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Sudeep Pharma Limited
―